PLIANT THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PLIANT THERAPEUTICS, INC. (PLRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.19M, a 34.35% decline year-over-year.
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.25M, a 52.27% decline year-over-year.
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $6.42M, a 27.88% decline year-over-year.
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.38M, a 40.08% decline year-over-year.
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $26.23M, a 30.28% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $37.63M, a 15.41% decline from fiscal 2023.
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $44.48M, a 96.84% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $22.60M, a 116.52% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.19M 10-Q · filed 2026-08-11 | $8.44M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $4.25M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $26.23M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $6.42M 10-Q · filed 2025-11-06 | $12.80M derived: sum of 2 quarters · filed 2026-08-11 | $21.71M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $6.38M 10-Q · filed 2026-08-11 | $15.29M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $8.91M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $37.63M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $8.90M 10-Q · filed 2025-11-06 | $19.54M derived: sum of 2 quarters · filed 2025-11-06 | $29.21M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $10.64M 10-Q · filed 2025-11-06 | $20.31M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $9.67M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $44.48M 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $10.36M 10-Q · filed 2024-11-07 | $23.41M derived: sum of 2 quarters · filed 2024-11-07 | $35.33M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $13.05M 10-Q · filed 2024-11-07 | $24.97M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $11.92M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $22.60M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $4.81M 10-Q · filed 2023-11-09 | $8.21M derived: sum of 2 quarters · filed 2023-11-09 | $11.74M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $3.40M 10-Q · filed 2023-11-09 | $6.93M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $3.53M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $10.44M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $2.81M 10-Q · filed 2022-11-08 | $5.09M derived: sum of 2 quarters · filed 2022-11-08 | $7.67M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $2.28M 10-Q · filed 2022-11-08 | $4.86M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $2.58M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $3.90M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $1.17M 10-Q · filed 2021-11-09 | $1.96M derived: sum of 2 quarters · filed 2021-11-09 | $2.38M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $786.00K 10-Q · filed 2021-11-09 | $1.21M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $425.00K 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $1.83M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $480.00K 10-Q · filed 2020-11-10 | $986.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.30M derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $506.00K 10-Q · filed 2020-11-10 | $818.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $312.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |